| Document |
Document Title |
|
WO/2015/054476A1 |
Methods of halogenating a carbon containing compound having an sp3 C-H bond are provided. Methods of fluorinating a carbon containing compound comprising halogenation with Cl or Br followed by nucleophilic substitution with F are provide...
|
|
WO/2015/042685A1 |
Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhi...
|
|
WO/2015/039172A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
|
|
WO/2015/031725A1 |
The present invention provides novel transition metal complexes (e.g., complexes of any one of Formulae (C1) to (C25)) that include an amine-N-oxide motif. The invention also provides methods of using these transition metal complexes in ...
|
|
WO/2014/096864A9 |
The present subject matter relates generally to compounds having the formula (I): wherein each of X, Y, R1, R2, R3, R4, and n are as defined herein. Compounds of formula (I) may act as inhibitors of the thioredoxin reductase enzyme syste...
|
|
WO/2015/029248A1 |
This negative electrode active material-coating material for lithium ion secondary batteries is a polyvinyl polymer which comprises a main chain and a branched chain that has a functional group containing an SO2NSO2CF3X group. In this co...
|
|
WO/2015/014900A1 |
The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with th...
|
|
WO/2015/016293A1 |
[Problem] To provide a novel drug for improving insulin resistance. [Solution] Benzenesulfonylamino)benzamide derivatives represented by the following general formula (1) (where R1 and R2 are as indicated in the description) or salts the...
|
|
WO/2015/010065A1 |
The invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: (I). The invention also provides pharmaceutically acceptable compositions comprising the compounds of ...
|
|
WO/2015/009977A1 |
The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ...
|
|
WO/2015/007870A1 |
The present invention relates to new compounds for treating, preventing or inhibiting a parasitic disease, preferably toxoplasmosis in a subject, the method for preparing thereof.
|
|
WO/2015/005051A1 |
Provided are a compound and an active light sensitive or radiation sensitive resin composition, which are capable of forming an ultrafine pattern (for example, one having a line width of 50 nm or less), while satisfying high sensitivity,...
|
|
WO/2015/002918A1 |
There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, suc...
|
|
WO/2015/001020A1 |
The preparation of a compound of formula (I) comprising an -SO2F function by reacting a compound of formula (II) with a fluorinating agent chosen from hydrofluoric acid and an ionic fluoride of a monovalent or divalent cation is describe...
|
|
WO/2013/156871A9 |
The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted n...
|
|
WO/2014/207445A1 |
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4- methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-met...
|
|
WO/2014/203944A1 |
The present invention addresses the problem of providing an aldol reaction catalyst and a method for producing a stereoselective cyclic β-hydroxy aldehyde compound using this catalyst. As a means for solving the above-mentioned problem,...
|
|
WO/2014/202765A1 |
The present invention provides an asymmetric and economic synthesis of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H-benzo[d]azepine via novel intermediates applying an asymmetric enzymatic, biomimetic or catalytic reduction. The present inve...
|
|
WO/2014/198880A1 |
The invention provides a compound of formula (I) wherein R2-R10 represent different meanings, and pharmaceutically acceptable salts thereof. The invention also provides synthetic procedures for preparing the compounds of formula (I), pha...
|
|
WO/2014/190015A1 |
Inhibitors that are anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as heart failure and autoimmune diseases.
|
|
WO/2014/183221A1 |
Resveratrol analogs and their use to inhibit Kv1.5 channels are provided. The resveratrol analogs are useful in the treatment of atrial arrhythmias, including atrial fibrillation (AF). Exemplary resveratrol analogs are compounds of gener...
|
|
WO/2014/175317A1 |
The problem is to provide a pharmaceutical for the prevention or treatment of hyperphosphatemia. Solution: A compound having general formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, R1: methyl group or the like...
|
|
WO/2014/167481A1 |
The present invention relates to novel synthetic analogues of xanthohumol and the use thereof.
|
|
WO/2014/162122A1 |
There is provided a compound of formula (I), which compound has antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the S...
|
|
WO/2014/157534A1 |
An electrolytic solution for non-aqueous secondary batteries which includes at least one specific aromatic compound selected from (A) and (B), an electrolyte, and an organic solvent. (A) An aromatic compound having three or more fused or...
|
|
WO/2014/157635A1 |
The purpose of the present invention is to provide a drug that demonstrates a pharmaceutical effect by having high mobility to the mid-brain and converting to bumetanide in the mid-brain, which is the primary site of epilepsy. The presen...
|
|
WO/2014/148258A1 |
The present invention provides a method for producing a disulfonylamine alkali metal salt, which comprises the steps of: carrying out a cation exchange reaction of a disulfonylamine onium salt represented by formula [I] (wherein R1 and R...
|
|
WO/2014/140059A1 |
Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, X5, X6, Y, Z, G, R1a, R2a, R1b, R2b, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the co...
|
|
WO/2014/143561A1 |
Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may b...
|
|
WO/2014/143659A1 |
Irreversible inhibitors of K-Ras, H-Ras or N-ras protein comprising a G12C mutation are provided. Also disclosed are methods to regulate the activity of K-Ras, H-Ras or N-ras protein comprising G12C mutation and methods to disease mediat...
|
|
WO/2014/136977A1 |
A photocurable composition excellent in the effect of reducing the mold releasing force even in a small amount of light exposure, and a photosensitive gas generating agent contained in the photocurable composition are provided. The photo...
|
|
WO/2014/135617A1 |
The invention discloses compounds of Formula (I). The compounds of formula (I) are TRPA1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the in...
|
|
WO/2014/133187A1 |
There is provided a pattern forming method comprising (i) a step of forming a film containing an actinic ray-sensitive or radiation-sensitive resin composition containing (A) a compound represented by the specific formula, (B) a compound...
|
|
WO/2014/131847A1 |
Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes f...
|
|
WO/2014/125075A1 |
The present invention relates to a antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which comprise carbon, sulphur, nitrog...
|
|
WO/2014/123203A1 |
Provided is a compound having PTP-1B inhibitory activity that is excellent as a drug, or a pharmaceutically acceptable salt thereof. A compound represented by general formula (I) (in the formula, each symbol means the same as in the spec...
|
|
WO/2014/119698A1 |
There is provided an actinic ray-sensitive or radiation-sensitive resin composition comprising: (A) a resin having a group capable of decomposing by an action of an acid to produce a polar group, (C1) a compound containing a group capabl...
|
|
WO/2014/118418A1 |
The invention relates to novel inhibitors of the enzyme isoprenylcysteine carboxyl methyltransferase, to the synthesis methods thereof, and to the use thereof as antitumour agents. Said inhibitors are derived from aliphatic amines and ar...
|
|
WO/2014/111113A1 |
The present invention relates to compounds of formula (I) and, in particular, drugs containing at least one compound of formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states, in the cause...
|
|
WO/2014/108806A2 |
The present invention provides a novel method for preparing compounds N-(4-nitro-2- sulfamoyl-phenyl)-malonamic acid methyl ester and N-(4-amino-2-sulfamoyl-phenyl)- malonamic acid methyl ester, which are novel intermediates for preparin...
|
|
WO/2014/106362A1 |
The present invention provides a preparation method of imidodisulfuryl fluoride lithium, comprising: obtaining an imidodisulfuryl fluoride lithium product by a metathesis reaction of lithium bis(oxalate)borate or lithium difluoro(oxalato...
|
|
WO/2014/104400A1 |
Provided is an actinic-ray- or radiation-sensitive resin composition including a resin (A) and any of compounds (B) of general formula (I) below. (In general formula (I), Rf represents a fluorine atom or a monovalent organic group contai...
|
|
WO/2014/095757A1 |
The present invention relates to methods and pharmaceutical compositions for the treatment of X-linked Charcot-Marie-Tooth. In particular, the present invention relates to a method for the treatment of CMTX in a subject in need thereof c...
|
|
WO/2014/097881A1 |
[Problem] The purpose of the present invention is to provide a thermal recording body that has both excellent color development performance and thermal discoloration resistance in blank sections, and that offers excellent barcode readabi...
|
|
WO/2014/089680A1 |
The invention relates to benzophenone-terminated quaternary ammonium compounds, processes for preparing benzophenone-terminated quaternary ammonium compounds, environmentally friendly antimicrobial formulations of said quaternary ammoniu...
|
|
WO/2014/090710A1 |
Compounds of the formula Ia or Ib, or pharmaceutically acceptable salts thereof, wherein m, n, r, A, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds and u...
|
|
WO/2014/087998A1 |
A sulfonium salt compound shown by general formula (I). (In the formula, R1 and R2 are mutually the same or different and show an alkyl group having 1-18 carbon atoms, R3 and R4 are mutually the same or different and show an alkyl group ...
|
|
WO/2014/083384A1 |
Benzenesulfonamide compounds potentiate 2,4-D induced embryogenesis in plants. In particular, 4-chloro-N-methyl-N-(2-methylphenyl) benzenesulfonamide and analogs induce somatic embryogenesis in plants. Methods of inducing somatic embryog...
|
|
WO/2014/085633A1 |
Provided herein are substituted biaryl sulfonamide compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the t...
|
|
WO/2014/080615A1 |
The present invention addresses the problem of providing a recording material and a recording sheet, each of which is produced using, as a color developer, a non-phenol compound that does not act as an endocrine disruptor and is therefor...
|
